Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (MIRM) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the 42^nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 10:30 a.m. PT.

The presentation and question and answer session will be webcast live and can be accessed by visiting the Investors and Media section of Mirum’s corporate website. The replay of the webcast will be available for 30 days.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. Cholbam is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme defects and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. Chenodal has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an iBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240103985129/en/

Investor Contacts:

Andrew McKibben

ir@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

What is the event Mirum Pharmaceuticals, Inc. (MIRM) will be presenting at?

Mirum Pharmaceuticals, Inc. (MIRM) will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

When will the presentation take place?

The presentation will take place on Wednesday, January 10, 2024 at 10:30 a.m. PT.

Where can the webcast be accessed?

The webcast can be accessed by visiting the Investors and Media section of Mirum’s corporate website.

How long will the webcast be available for replay?

The replay of the webcast will be available for 30 days.